Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Aug 1;176(2):531–541. doi: 10.1084/jem.176.2.531

Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R

PMCID: PMC2119323  PMID: 1500859

Abstract

Interleukin 2 (IL-2) receptors expressed on the surface of activated T cells and natural killer (NK) cells exhibit a variety of affinity states depending on their subunit composition. Low-affinity binding is associated with a 55-kDa alpha chain, intermediate-affinity binding with a 70-75-kD beta chain, and high-affinity binding with a bimolecular complex of the alpha and beta subunits. In a previous study of the IL-2 receptors expressed on NK cells obtained from cancer patients after in vivo IL-2 therapy, we documented a discrepancy between the level of beta chain and the level of intermediate-affinity IL-2 binding sites expressed on the cell surface. Based on this result, we postulated that formation of intermediate-affinity receptor sites required a component in addition to the beta chain, and that this component was present at limiting levels in the patient NK cells. In the present study we have examined the structure of the intermediate- affinity receptor complex using monoclonal antibodies that recognize the beta chain, but that do not interfere with its ability to bind IL- 2. Evidence is presented establishing the physical association of a novel protein of 64 kD with the beta chain in intermediate-affinity IL- 2 binding sites. This molecule, termed IL-2R gamma chain, coprecipitated with beta chains prepared from cells that had been incubated with IL-2, but was undetectable in immunoprecipitates prepared in the absence of IL-2. Examination of gamma chain expression in post-IL-2 therapy NK cells, where only low levels of intermediate- affinity IL-2 binding were detectable, revealed that the gamma chain was associated with, on average, only 10-12% of the beta chains expressed on such cells. This contrasted with approximately equal levels of beta and gamma chain expression on YT cells, a cell line that has both high levels of cell surface beta chain expression and high levels of IL-2 binding. Thus, the ratio of gamma chain to beta chain present in the immunoprecipitates roughly correlated with the proportion of beta chain involved in intermediate-affinity receptor sites. This result suggests that the 64-kD gamma chain is the component responsible for regulating the affinity of IL-2 association with the beta subunit. By further defining the structural components necessary for IL-2 receptor formation, these studies provide additional insight into mechanisms whereby lymphocytes might regulate their responsiveness to IL-2.

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Caligiuri M., O'Brien C., Manley T., Ritz J., Schlossman S. F. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2274–2278. doi: 10.1073/pnas.87.6.2274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asao H., Takeshita T., Nakamura M., Nagata K., Sugamura K. Interleukin 2 (IL-2)-induced tyrosine phosphorylation of IL-2 receptor p75. J Exp Med. 1990 Mar 1;171(3):637–644. doi: 10.1084/jem.171.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asao H., Takeshita T., Nakamura M., Nagata K., Sugamura K. The evidence for the IL-2 receptor beta chain processing from p70 to p75. Int Immunol. 1990;2(5):469–472. doi: 10.1093/intimm/2.5.469. [DOI] [PubMed] [Google Scholar]
  4. Bogner M. P., Voss S. D., Bechhofer R., Hank J. A., Roper M., Poplack D., Hammond D., Sondel P. M. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991) 1992 Feb;11(2):111–118. [PubMed] [Google Scholar]
  5. Colamonici O. R., Neckers L. M., Rosolen A. Putative gamma-subunit of the IL-2 receptor is detected in low, intermediate, and high affinity IL-2 receptor-bearing cells. J Immunol. 1990 Jul 1;145(1):155–160. [PubMed] [Google Scholar]
  6. Cosman D., Lyman S. D., Idzerda R. L., Beckmann M. P., Park L. S., Goodwin R. G., March C. J. A new cytokine receptor superfamily. Trends Biochem Sci. 1990 Jul;15(7):265–270. doi: 10.1016/0968-0004(90)90051-c. [DOI] [PubMed] [Google Scholar]
  7. Dukovich M., Wano Y., Le thi Bich Thuy, Katz P., Cullen B. R., Kehrl J. H., Greene W. C. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature. 1987 Jun 11;327(6122):518–522. doi: 10.1038/327518a0. [DOI] [PubMed] [Google Scholar]
  8. Farrar W. L., Ferris D. K. Two-dimensional analysis of interleukin 2-regulated tyrosine kinase activation mediated by the p70-75 beta subunit of the interleukin 2 receptor. J Biol Chem. 1989 Jul 25;264(21):12562–12567. [PubMed] [Google Scholar]
  9. Fung M. R., Ju G., Greene W. C. Co-internalization of the p55 and p70 subunits of the high-affinity human interleukin 2 receptor. Evidence for a stable ternary receptor complex. J Exp Med. 1988 Nov 1;168(5):1923–1928. doi: 10.1084/jem.168.5.1923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fung M. R., Scearce R. M., Hoffman J. A., Peffer N. J., Hammes S. R., Hosking J. B., Schmandt R., Kuziel W. A., Haynes B. F., Mills G. B. A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. J Immunol. 1991 Aug 15;147(4):1253–1260. [PubMed] [Google Scholar]
  11. Hatakeyama M., Kono T., Kobayashi N., Kawahara A., Levin S. D., Perlmutter R. M., Taniguchi T. Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science. 1991 Jun 14;252(5012):1523–1528. doi: 10.1126/science.2047859. [DOI] [PubMed] [Google Scholar]
  12. Hatakeyama M., Mori H., Doi T., Taniguchi T. A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization. Cell. 1989 Dec 1;59(5):837–845. doi: 10.1016/0092-8674(89)90607-7. [DOI] [PubMed] [Google Scholar]
  13. Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science. 1989 May 5;244(4904):551–556. doi: 10.1126/science.2785715. [DOI] [PubMed] [Google Scholar]
  14. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec 21;63(6):1149–1157. doi: 10.1016/0092-8674(90)90411-7. [DOI] [PubMed] [Google Scholar]
  15. Johnston R. F., Pickett S. C., Barker D. L. Autoradiography using storage phosphor technology. Electrophoresis. 1990 May;11(5):355–360. doi: 10.1002/elps.1150110503. [DOI] [PubMed] [Google Scholar]
  16. Lanier L. L., Yu G., Phillips J. H. Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature. 1989 Dec 14;342(6251):803–805. doi: 10.1038/342803a0. [DOI] [PubMed] [Google Scholar]
  17. Lowenthal J. W., Greene W. C. Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor. J Exp Med. 1987 Oct 1;166(4):1156–1161. doi: 10.1084/jem.166.4.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Michiel D. F., Garcia G. G., Evans G. A., Farrar W. L. Regulation of the interleukin 2 receptor complex tyrosine kinase activity in vitro. Cytokine. 1991 Sep;3(5):428–438. doi: 10.1016/1043-4666(91)90047-h. [DOI] [PubMed] [Google Scholar]
  19. Mills G. B., May C., McGill M., Fung M., Baker M., Sutherland R., Greene W. C. Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. J Biol Chem. 1990 Feb 25;265(6):3561–3567. [PubMed] [Google Scholar]
  20. Miltenyi S., Müller W., Weichel W., Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11(2):231–238. doi: 10.1002/cyto.990110203. [DOI] [PubMed] [Google Scholar]
  21. Minamoto S., Mori H., Hatakeyama M., Kono T., Doi T., Ide T., Uede T., Taniguchi T. Characterization of the heterodimeric complex of human IL-2 receptor alpha.beta chains reconstituted in a mouse fibroblast cell line, L929. J Immunol. 1990 Oct 1;145(7):2177–2182. [PubMed] [Google Scholar]
  22. Ohbo K., Takeshita T., Asao H., Kurahayashi Y., Tada K., Mori H., Hatakeyama M., Taniguchi T., Sugamura K. Monoclonal antibodies defining distinct epitopes of the human IL-2 receptor beta chain and their differential effects on IL-2 responses. J Immunol Methods. 1991 Aug 28;142(1):61–72. doi: 10.1016/0022-1759(91)90293-o. [DOI] [PubMed] [Google Scholar]
  23. Ringheim G. E., Freimark B. D., Robb R. J. Quantitative characterization of the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its modulation by the alpha chain and a second affinity-modulating element. Lymphokine Cytokine Res. 1991 Jun;10(3):219–224. [PubMed] [Google Scholar]
  24. Robb R. J., Greene W. C. Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med. 1987 Apr 1;165(4):1201–1206. doi: 10.1084/jem.165.4.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robb R. J., Greene W. C., Rusk C. M. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med. 1984 Oct 1;160(4):1126–1146. doi: 10.1084/jem.160.4.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Robb R. J., Rusk C. M., Yodoi J., Greene W. C. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2002–2006. doi: 10.1073/pnas.84.7.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Saito Y., Tada H., Sabe H., Honjo T. Biochemical evidence for a third chain of the interleukin-2 receptor. J Biol Chem. 1991 Nov 25;266(33):22186–22191. [PubMed] [Google Scholar]
  28. Saltzman E. M., Thom R. R., Casnellie J. E. Activation of a tyrosine protein kinase is an early event in the stimulation of T lymphocytes by interleukin-2. J Biol Chem. 1988 May 25;263(15):6956–6959. [PubMed] [Google Scholar]
  29. Shackelford D. A., Trowbridge I. S. Ligand-stimulated tyrosine phosphorylation of the IL-2 receptor beta chain and receptor-associated proteins. Cell Regul. 1991 Jan;2(1):73–85. doi: 10.1091/mbc.2.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sharon M., Gnarra J. R., Leonard W. J. The beta-chain of the IL-2 receptor (p70) is tyrosine-phosphorylated on YT and HUT-102B2 cells. J Immunol. 1989 Oct 15;143(8):2530–2533. [PubMed] [Google Scholar]
  31. Sharon M., Klausner R. D., Cullen B. R., Chizzonite R., Leonard W. J. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science. 1986 Nov 14;234(4778):859–863. doi: 10.1126/science.3095922. [DOI] [PubMed] [Google Scholar]
  32. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  33. Sosman J. A., Kohler P. C., Hank J. A., Moore K. H., Bechhofer R., Storer B., Sondel P. M. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst. 1988 Nov 16;80(18):1451–1461. doi: 10.1093/jnci/80.18.1451. [DOI] [PubMed] [Google Scholar]
  34. Sugamura K., Takeshita T., Asao H., Kumaki S., Ohbo K., Ohtani K., Nakamura M. IL-2-induced signal transduction: involvement of tyrosine kinase and IL-2 receptor gamma chain. Lymphokine Res. 1990 Winter;9(4):539–542. [PubMed] [Google Scholar]
  35. Suzuki J., Takeshita T., Ohbo K., Asao H., Tada K., Sugamura K. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody. Int Immunol. 1989;1(4):373–377. doi: 10.1093/intimm/1.4.373. [DOI] [PubMed] [Google Scholar]
  36. Takeshita T., Asao H., Suzuki J., Sugamura K. An associated molecule, p64, with high-affinity interleukin 2 receptor. Int Immunol. 1990;2(5):477–480. doi: 10.1093/intimm/2.5.477. [DOI] [PubMed] [Google Scholar]
  37. Takeshita T., Goto Y., Tada K., Nagata K., Asao H., Sugamura K. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor. J Exp Med. 1989 Apr 1;169(4):1323–1332. doi: 10.1084/jem.169.4.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Takeshita T., Ohtani K., Asao H., Kumaki S., Nakamura M., Sugamura K. An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex. J Immunol. 1992 Apr 1;148(7):2154–2158. [PubMed] [Google Scholar]
  39. Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med. 1987 Jan 1;165(1):223–238. doi: 10.1084/jem.165.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tsudo M., Karasuyama H., Kitamura F., Tanaka T., Kubo S., Yamamura Y., Tamatani T., Hatakeyama M., Taniguchi T., Miyasaka M. The IL-2 receptor beta-chain (p70). Ligand binding ability of the cDNA-encoding membrane and secreted forms. J Immunol. 1990 Jul 15;145(2):599–606. [PubMed] [Google Scholar]
  41. Tsudo M., Kitamura F., Miyasaka M. Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1982–1986. doi: 10.1073/pnas.86.6.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Voss S. D., Robb R. J., Weil-Hillman G., Hank J. A., Sugamura K., Tsudo M., Sondel P. M. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med. 1990 Oct 1;172(4):1101–1114. doi: 10.1084/jem.172.4.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Waldmann T. A. The interleukin-2 receptor. J Biol Chem. 1991 Feb 15;266(5):2681–2684. [PubMed] [Google Scholar]
  44. Waldmann T. A. The multi-subunit interleukin-2 receptor. Annu Rev Biochem. 1989;58:875–911. doi: 10.1146/annurev.bi.58.070189.004303. [DOI] [PubMed] [Google Scholar]
  45. Wang H. M., Smith K. A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987 Oct 1;166(4):1055–1069. doi: 10.1084/jem.166.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Weil-Hillman G., Voss S. D., Fisch P., Schell K., Hank J. A., Sosman J. A., Sugamura K., Sondel P. M. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 1990 May 1;50(9):2683–2691. [PubMed] [Google Scholar]
  47. Wolff J., Covelli I. Iodination of the normal and buried tyrosyl residues of lysozyme. II. Spectrophotometric analysis. Biochemistry. 1966 Mar;5(3):867–871. doi: 10.1021/bi00867a009. [DOI] [PubMed] [Google Scholar]
  48. Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T., Takigawa M., Sasaki M., Minato N., Tsudo M. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985 Mar;134(3):1623–1630. [PubMed] [Google Scholar]
  49. Zurawski S. M., Imler J. L., Zurawski G. Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction. EMBO J. 1990 Dec;9(12):3899–3905. doi: 10.1002/j.1460-2075.1990.tb07610.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES